<DOC>
	<DOCNO>NCT00075621</DOCNO>
	<brief_summary>RATIONALE : Autologous stem cell transplantation may effective treatment primary systemic ( AL ) amyloidosis . PURPOSE : This phase II trial study well tandem ( two ) autologous stem cell transplantation work treat patient primary systemic ( AL ) amyloidosis .</brief_summary>
	<brief_title>Tandem Autologous Stem Cell Transplantation Treating Patients With Primary Systemic ( AL ) Amyloidosis</brief_title>
	<detailed_description>OBJECTIVES : - Determine tolerability tandem autologous stem cell transplantation patient AL amyloidosis . - Determine whether regimen convert hematologic non-complete response ( CR ) CR patient . - Determine overall survival patient treat regimen . OUTLINE : - First transplantation : Patients receive filgrastim ( G-CSF ) subcutaneously daily begin 3 day initiation stem cell collection continue day completion stem cell collection . Patients may undergo bone marrow harvest inadequate number peripheral blood stem cell collect . Patients receive high-dose melphalan IV 20 minute day -3 -2 . Patients undergo autologous stem cell transplantation ( ASCT ) day 0 . - Second transplantation : Within 6-12 month first ASCT , patient achieve complete response receive high-dose melphalan IV 20 minute day -3 -2 second ASCT day 0 . Treatment continue absence unacceptable toxicity . Patients follow 3 6 month , 1 year , annually thereafter . PROJECTED ACCRUAL : A total 62 patient accrue study within 2-3 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm AL amyloidosis , meet 1 follow criterion : Plasma cell dyscrasia , evidence 1 following : Monoclonal protein serum urine immunofixation electrophoresis Plasmacytosis bone marrow monoclonal staining kappa lambda light chain isotype Macroglossia least 1 site biopsy proven amyloidosis absence mutant transthyretin rule PATIENT CHARACTERISTICS : Age 18 65 Performance status SWOG 02 Life expectancy At least 1 year Hematopoietic Not specify Hepatic Not specify Renal Not specify Cardiovascular LVEF ≥ 45 % MUGA echocardiogram Pulmonary DLCO ≥ 50 % Other Not pregnant nursing Fertile patient must use effective contraception Able tolerate 2 course highdose therapy HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Prior alkylating agent chemotherapy allow provide morphologic cytogenetic evidence myelodysplastic syndrome Prior total cumulative oral melphalan dose &lt; 300 mg Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other At least 4 week since prior cytotoxic therapy recover No senile , secondary , localize , dialysisrelated , familial amyloidosis No overt multiple myeloma ( e.g. , great 30 % bone marrow plasmacytosis , extensive [ 2 ] lytic lesion , hypercalcemia ) Cardiovascular No myocardial infarction within past 6 month No congestive heart failure No arrhythmia refractory therapy No evidence symptomatic transient ischemic attack stroke No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , adequately treated stage I II cancer currently complete remission</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>primary systemic amyloidosis</keyword>
</DOC>